Actinium Pharmaceuticals Inc. (NYSE American: ATNM) Attends 31st Annual ROTH Conference
Actinium Pharmaceuticals (NYSE American: ATNM), with its proprietary, chemotherapy free or sparing, targeted conditioning technology, is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC's or Antibody Radiation Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. For more information, visit the company's website at www.actiniumpharma.com About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides…







